Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 707

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 3
Chunk 707
---
 to us more recently will help protect the proprietary nature of our
Hemopurifier treatment technology.

We believe that the Hemopurifier
may be a substantial advancement in the treatment of patients with advanced and metastatic cancer

In addition to the foregoing,
we are monitoring closely the impact of inflation, recent bank failures and the war between Russia and Ukraine and the military conflicts
in Israel and the surrounding areas, as well as related political and economic responses and counter-responses by various global factors
on our business. Given the level of uncertainty regarding the duration and impact of these events on capital markets and the U.S. economy,
we are unable to assess the impact on our timelines and future access to capital. The full extent to which inflation, recent bank failures
and the ongoing military conflicts will impact our business, results of operations, financial condition, clinical trials and preclinical
research will depend on future developments, as well as the economic impact on national and international markets that are highly uncertain. 

LIQUIDITY AND GOING CONCERN

The Company has incurred losses since inception
in devoting substantially all of its efforts toward research and development and has an accumulated deficit of $167,954,817 as of March
31, 2025. During the year ended March 31, 2025, the Company generated a net loss of approximately $13,388,000 and the Company expects
that it will continue to generate operating losses for the foreseeable future. While the Company has been carrying out certain expense
reductions since November 2023; our planned additional expense reductions may not materialize and/or our patient recruitment may occur
more rapidly than expected along with the concomitant increases in expenses, therefore there is substantial doubt that our cash on hand
will carry the company for 12 months beyond the filing date of the financial statements included in this Annual Report.

The Company’s ability to execute its current
operating plan depends on its ability to reduce expenses and obtain additional funding via the sale of equity, or other sources of capital.
The Company plans to continue actively pursuing financing alternatives, however, there can be no assurance that it will obtain the necessary
funding, raising substantial doubt about the Company’s ability to continue as a going concern within one year of the date these
financial statements are issued. The accompanying financial statements do not include any adjustments that might result from the outcome
of this uncertainty.

PRINCIPLES OF CONSOLIDATION

The accompanying consolidated financial statements
include the accounts of A